Advance Copy
Accessed: 08.03.2020
Как и руководство 2006 года, настоящий документ предназначен для специалистов,
занимающихся разработкой государственных программ по борьбе с туберкулезом, педиатр...ов и других работников здравоохранения в странах с низким и средним уровнем дохода. Эти рекомендации не подходят для стран с высоким уровнем дохода, где распространенность ТБ невысока. Особенно важно проводить это различие при выборе методов диагностики и обследовании контактных лиц.
more
Strengthening Community responses to HIv Treatment and Prevention
Non-communicable diseases (NCDs) are of increasing concern for society and national governments, as well as globally due to their high mortality rate. The main risk factors of NCDs can be classified into the categories of self-management, genetic factors, environmental factors, factors of medical co...nditions, and socio-demographic factors.
more
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
Countdown to zero
2011- 2015
Stories of putting people at the centre
Accessed: 20.11.2019
Making education more inclusive requires schools and education authorities to remove the barriers to education experienced by the most excluded children - often the poorest, children with disabilities, children without family care, girls, or children from minority groups. Also included in the text a...re examples of children from very remote areas, girls excluded from school, children from ethnic groups, children with language barriers, and children in countries affected by conflict.
more
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID-19 doses, stimulated new resolve to address future... supply security. In 2021, the AU set a target to produce and supply more than 60% of the vaccine doses on the continent by 2040.
In the last 18 months alone, more than 30 new African manufacturing projects have been announced and estimates indicate that the African vaccine market across all existing and projected novel products could range between US$ 2.8 billion and US$ 5.6 billion by 2040*, demonstrating the potential for a thriving regional industry to emerge.
more